Our team is currently conducting a prospective study in the pediatric ICU population to integrate a real time AKI risk assessment algorithm, the renal angina index (5–7), with urine AKI biomarker assessment (Neutrophil Gelatinase Associated Lipocalin, NGAL, BioPorto, Inc.), to guide fluid management and renal replacement therapy initiation (TAKING FOCUS 2, NCT03541785, 2P50 DK096418-06). This evidence concerns the gene LCN2 and acute kidney injury.